Ocular Therapeut (OCUL)

$9.16 -0.34 (-3.58%)
Market Cap 2.02B
Revenue (ttm) 51.95M
Net Income (ttm) -265.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -511.92%
Debt to Equity Ratio 0.12
Volume 2,373,700
Avg Vol 3,536,080
Day's Range N/A - N/A
Shares Out 218.96M
Stochastic %K 54%
Beta 0.93
Analysts Strong Sell
Price Target $25.83

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Address:
15 Crosby Drive, Bedford, United States
phonesearch
phonesearch May. 15 at 6:49 PM
$OCUL this stock market is so insane and doesn't reflect reality. Who are you going to believe ..... Wall Street? ... Or the medical experts and regulatory analysis who view the trial as a landmark achievement noting it's the first time triosine kinase inhibitors insert has ever demonstrated monotherapy. It doesn't take a rocket scientist to figure that one out.
1 · Reply
ShortSuckieTuckie
ShortSuckieTuckie May. 15 at 4:12 PM
$OCUL Latest Institutional Changes from Q1
2 · Reply
CapSampler
CapSampler May. 15 at 3:09 PM
$GLSI one day will be the day. When this gets the billions market cap like $MBX $OCUL etc. God we’ve been waiting for quite sometime now.
0 · Reply
Tmoney85285
Tmoney85285 May. 15 at 2:40 PM
$OCUL anyone with half a brain realizes that they are not buying for the long term- they are buying to short. this probably heads to roughly $6 before they let it run. follow the big money, not the moron who uses AI to make juvenile memes.
2 · Reply
TBillyhatesmoney
TBillyhatesmoney May. 15 at 1:43 PM
$OCUL Deep Track goes deeper raising stake to almost 21 MM shares. 85% increase and 9.5% ownership in OCUL
0 · Reply
Tmoney85285
Tmoney85285 May. 15 at 1:36 PM
$OCUL wow, another rip roaring day for pravin and the dream team. love the comments yesterday only for the gains to be wiped out in what, 3 minutes? complete joke of a company- sad to see so many people who are being tricked.
0 · Reply
Bbbb44444
Bbbb44444 May. 15 at 1:08 PM
$OCUL “Extremely Bearish” sentiment? Lol, ST is so stupid. Great counter-indicator though.
0 · Reply
HedgeFollow
HedgeFollow May. 15 at 11:39 AM
. 🔍 𝗡𝗘𝗪 13𝗙 𝗥𝗘𝗟𝗘𝗔𝗦𝗘𝗗 🔎 5-star Hedge Fund RATAN just filed their 13F. Most Notable Trades: 𝗡𝗲𝘄 𝗟𝗔𝗥𝗚𝗘 𝗕𝘂𝘆𝘀: $OCUL, $LITE, $APLD 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 by 50%: $APP, $BA and BLoom energy 𝗦𝗢𝗟𝗗 out: Unity software and Oracle RATAN is up 183.56% in past 3 yrs. Source: hedgefollow.com/funds/Ratan+Capital+Management
1 · Reply
Sowa5000
Sowa5000 May. 14 at 9:09 PM
$OCUL like this one here. Good time to accumulate.
0 · Reply
rizzato
rizzato May. 14 at 8:07 PM
$OCUL better 500.000 added than sold for me but not for you probably
0 · Reply
Latest News on OCUL
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026, 7:00 AM EDT - 12 hours ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 6:40 PM EDT - 3 days ago

Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2026, 4:05 PM EDT - 7 days ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 10 days ago

Ocular Therapeutix Earnings Call Transcript: Q1 2026

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

2026-05-05T11:59:32.000Z - 10 days ago

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

May 5, 2026, 7:00 AM EDT - 10 days ago

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix enrolls first patient in Axpali trial

2026-04-29T13:00:19.000Z - 16 days ago

Ocular Therapeutix enrolls first patient in Axpali trial

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Apr 29, 2026, 7:00 AM EDT - 16 days ago

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Apr 28, 2026, 7:00 AM EDT - 17 days ago

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Ocular Therapeutix Transcript: HCW @ Home

Apr 27, 2026, 2:30 PM EDT - 18 days ago

Ocular Therapeutix Transcript: HCW @ Home

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Apr 22, 2026, 7:00 AM EDT - 23 days ago

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Ocular Therapeutix reports additional Axpaxli trial data

2026-04-13T11:22:45.000Z - 4 weeks ago

Ocular Therapeutix reports additional Axpaxli trial data

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Apr 13, 2026, 7:00 AM EDT - 4 weeks ago

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Apr 1, 2026, 7:00 AM EDT - 6 weeks ago

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Ocular Therapeutix Transcript: RBC Capital Markets Virtual Ophthalmology Conference

Mar 25, 2026, 9:30 AM EDT - 7 weeks ago

Ocular Therapeutix Transcript: RBC Capital Markets Virtual Ophthalmology Conference

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

Mar 20, 2026, 5:24 PM EDT - 2 months ago

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

EYPT

Ocular Therapeutix Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 9:00 AM EDT - 2 months ago

Ocular Therapeutix Transcript: The Citizens Life Sciences Conference 2026

Ocular Therapeutix price target raised to $27 from $24 at BofA

2026-03-03T11:45:13.000Z - 2 months ago

Ocular Therapeutix price target raised to $27 from $24 at BofA

Ocular Therapeutix price target raised to $28 from $21 at Clear Street

2026-03-02T21:05:53.000Z - 2 months ago

Ocular Therapeutix price target raised to $28 from $21 at Clear Street

Ocular Therapeutix Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 2 months ago

Ocular Therapeutix Transcript: TD Cowen 46th Annual Health Care Conference

Ocular Therapeutix Transcript: Study update

Mar 2, 2026, 7:30 AM EST - 2 months ago

Ocular Therapeutix Transcript: Study update

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 19, 2026, 10:41 AM EST - 3 months ago

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Ocular Therapeutix selloff brings attractive entry point, says Citizens

2026-02-17T19:15:34.000Z - 3 months ago

Ocular Therapeutix selloff brings attractive entry point, says Citizens

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

2026-02-17T15:55:17.000Z - 3 months ago

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

Ocular Therapeutix Transcript: Study result

Feb 17, 2026, 8:00 AM EST - 3 months ago

Ocular Therapeutix Transcript: Study result

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

2026-02-17T12:17:53.000Z - 3 months ago

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

Feb 17, 2026, 7:08 AM EST - 3 months ago

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

REGN

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Feb 13, 2026, 5:00 PM EST - 3 months ago

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 6, 2026, 4:01 PM EST - 3 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

2026-02-05T12:05:13.000Z - 3 months ago

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

Ocular Therapeutix appoints Robinson as Global Chief Commercial Officer

2026-01-21T12:05:23.000Z - 4 months ago

Ocular Therapeutix appoints Robinson as Global Chief Commercial Officer

MRK

Unusually active option classes on open January 16th

2026-01-16T14:40:19.000Z - 4 months ago

Unusually active option classes on open January 16th

CWAN FYBR ISRG LAC LAES LDI SGML

Sanofi prepping higher bid for Ocular Therapeutix, IBD reports

2026-01-15T16:06:19.000Z - 4 months ago

Sanofi prepping higher bid for Ocular Therapeutix, IBD reports

SNY

Ocular Therapeutix rises 11.7%

2026-01-15T15:06:31.000Z - 4 months ago

Ocular Therapeutix rises 11.7%

Ocular Therapeutix price target raised to $21 from $18 at BofA

2025-12-12T13:36:48.000Z - 5 months ago

Ocular Therapeutix price target raised to $21 from $18 at BofA

Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’

2025-12-09T16:15:28.000Z - 5 months ago

Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’

EYPT

Ocular Therapeutix up 13% at $14.22 on accelerated AXPAXLI NDA submission plans

2025-12-08T12:40:15.000Z - 5 months ago

Ocular Therapeutix up 13% at $14.22 on accelerated AXPAXLI NDA submission plans

Ocular announces plans to accelerate AXPAXLI NDA submission timeline

2025-12-08T12:11:15.000Z - 5 months ago

Ocular announces plans to accelerate AXPAXLI NDA submission timeline

Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright

2025-12-08T11:15:06.000Z - 5 months ago

Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright

Ocular Therapeutix reports inducement grant under Nasdaq listing rule

2025-12-05T12:05:31.000Z - 5 months ago

Ocular Therapeutix reports inducement grant under Nasdaq listing rule

Ocular Therapeutix Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:30 AM EST - 5 months ago

Ocular Therapeutix Transcript: Piper Sandler 37th Annual Healthcare Conference

Ocular Therapeutix Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 9:30 AM EST - 6 months ago

Ocular Therapeutix Transcript: Jefferies London Healthcare Conference 2025

Ocular Therapeutix Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 6 months ago

Ocular Therapeutix Earnings Call Transcript: Q3 2025

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 7:05 AM EST - 6 months ago

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Nov 4, 2025, 7:00 AM EST - 6 months ago

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Oct 7, 2025, 7:00 AM EDT - 7 months ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix Transcript: Investor Day 2025

Sep 30, 2025, 2:00 PM EDT - 8 months ago

Ocular Therapeutix Transcript: Investor Day 2025

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Sep 30, 2025, 7:08 AM EDT - 8 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Sep 30, 2025, 6:21 AM EDT - 8 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Ocular Therapeutix Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 12:50 PM EDT - 8 months ago

Ocular Therapeutix Transcript: Baird Global Healthcare Conference 2025

Ocular Therapeutix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 2:35 PM EDT - 8 months ago

Ocular Therapeutix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Ocular Therapeutix Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 2:00 PM EDT - 9 months ago

Ocular Therapeutix Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Ocular Therapeutix Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Ocular Therapeutix Earnings Call Transcript: Q2 2025

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 26, 2025, 1:54 PM EDT - 11 months ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Jun 16, 2025, 7:00 AM EDT - 11 months ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Ocular Therapeutix Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Stifel 2025 Virtual Ophthalmology Forum

Ocular Therapeutix Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 4:30 PM EDT - 1 year ago

Ocular Therapeutix Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Ocular Therapeutix Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 2:35 PM EDT - 1 year ago

Ocular Therapeutix Transcript: RBC Capital Markets Global Healthcare Conference 2025

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

May 14, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Ocular Therapeutix Transcript: Bank of America 2025 Healthcare Conference

May 13, 2025, 12:20 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Bank of America 2025 Healthcare Conference

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 9:00 AM EDT - 1 year ago

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference 2025

Ocular Therapeutix Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: 24th Annual Needham Virtual Healthcare Conference

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Ocular Therapeutix Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 10:00 AM EDT - 1 year ago

Ocular Therapeutix Transcript: Leerink Global Healthcare Conference 2025

Ocular Therapeutix Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:50 AM EST - 1 year ago

Ocular Therapeutix Transcript: TD Cowen 45th Annual Healthcare Conference

Ocular Therapeutix Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q4 2024

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 24, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Feb 3, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Jan 14, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Ocular Therapeutix Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:15 PM EST - 1 year ago

Ocular Therapeutix Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 1:30 PM EST - 1 year ago

Ocular Therapeutix Transcript: Piper Sandler 36th Annual Healthcare Conference

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Dec 2, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 26, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Ocular Therapeutix Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q3 2024

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 13, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Nov 6, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Ocular Therapeutix Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Ocular Therapeutix Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at September Retina Meetings

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Ocular Therapeutix Earnings Call Transcript: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q2 2024

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 31, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 13, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Ocular Therapeutix Transcript: Investor Day 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: Investor Day 2024

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 4, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix Transcript: BofA Securities 2024 Health Care Conference

May 15, 2024, 6:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: BofA Securities 2024 Health Care Conference

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 1:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference

Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2024, 8:16 PM EDT - 2 years ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

May 6, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

May 3, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

May 1, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Apr 18, 2024, 7:00 AM EDT - 2 years ago

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Apr 9, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

phonesearch
phonesearch May. 15 at 6:49 PM
$OCUL this stock market is so insane and doesn't reflect reality. Who are you going to believe ..... Wall Street? ... Or the medical experts and regulatory analysis who view the trial as a landmark achievement noting it's the first time triosine kinase inhibitors insert has ever demonstrated monotherapy. It doesn't take a rocket scientist to figure that one out.
1 · Reply
ShortSuckieTuckie
ShortSuckieTuckie May. 15 at 4:12 PM
$OCUL Latest Institutional Changes from Q1
2 · Reply
CapSampler
CapSampler May. 15 at 3:09 PM
$GLSI one day will be the day. When this gets the billions market cap like $MBX $OCUL etc. God we’ve been waiting for quite sometime now.
0 · Reply
Tmoney85285
Tmoney85285 May. 15 at 2:40 PM
$OCUL anyone with half a brain realizes that they are not buying for the long term- they are buying to short. this probably heads to roughly $6 before they let it run. follow the big money, not the moron who uses AI to make juvenile memes.
2 · Reply
TBillyhatesmoney
TBillyhatesmoney May. 15 at 1:43 PM
$OCUL Deep Track goes deeper raising stake to almost 21 MM shares. 85% increase and 9.5% ownership in OCUL
0 · Reply
Tmoney85285
Tmoney85285 May. 15 at 1:36 PM
$OCUL wow, another rip roaring day for pravin and the dream team. love the comments yesterday only for the gains to be wiped out in what, 3 minutes? complete joke of a company- sad to see so many people who are being tricked.
0 · Reply
Bbbb44444
Bbbb44444 May. 15 at 1:08 PM
$OCUL “Extremely Bearish” sentiment? Lol, ST is so stupid. Great counter-indicator though.
0 · Reply
HedgeFollow
HedgeFollow May. 15 at 11:39 AM
. 🔍 𝗡𝗘𝗪 13𝗙 𝗥𝗘𝗟𝗘𝗔𝗦𝗘𝗗 🔎 5-star Hedge Fund RATAN just filed their 13F. Most Notable Trades: 𝗡𝗲𝘄 𝗟𝗔𝗥𝗚𝗘 𝗕𝘂𝘆𝘀: $OCUL, $LITE, $APLD 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 by 50%: $APP, $BA and BLoom energy 𝗦𝗢𝗟𝗗 out: Unity software and Oracle RATAN is up 183.56% in past 3 yrs. Source: hedgefollow.com/funds/Ratan+Capital+Management
1 · Reply
Sowa5000
Sowa5000 May. 14 at 9:09 PM
$OCUL like this one here. Good time to accumulate.
0 · Reply
rizzato
rizzato May. 14 at 8:07 PM
$OCUL better 500.000 added than sold for me but not for you probably
0 · Reply
Tmoney85285
Tmoney85285 May. 14 at 5:39 PM
$OCUL wow, a total of 500K shares! holy smokes! look at the conviction- adding 3% of their current share allotment to their total holdings. LOOKOUT folks! everyone knows these guys are the ones shorting it- except for the bulls here
3 · Reply
TBillyhatesmoney
TBillyhatesmoney May. 14 at 4:24 PM
$OCUL so i guess BR did add last quarter. Tdummy wrong again
1 · Reply
Tmoney85285
Tmoney85285 May. 14 at 3:24 PM
$OCUL wow, another embarrassing day for this stock again. but please, tell me how amazing pravin's latest diatribe was. he's really knocking them dead and getting the street excited about how mediocre the drug is. i simply cannot believe you guys really think this is going anywhere. this short will continue to reap profits as the bandaid slowly gets pulled off until one day, the bottom falls out. keep on being hopeful, everyone!
0 · Reply
davetoma
davetoma May. 14 at 3:12 PM
$OCUL but when stock is down 7 cents tmoney goes on his pulpit....I CALLED THIS WAS GOING SUB 9 lolol camt have it both ways
0 · Reply
Bbbb44444
Bbbb44444 May. 14 at 1:26 PM
$OCUL I swear ST sentiment is such a good counter-indicator.
0 · Reply
WarrenDouglasTrader
WarrenDouglasTrader May. 14 at 1:00 PM
$OCUL File the NDA already Pravin!
0 · Reply
Tmoney85285
Tmoney85285 May. 14 at 12:03 PM
$OCUL you went up 7 cents. embarrassing. stock is a joke and anyone who thought pravins last talk was encouraging needs help.
0 · Reply
Fairvalue10
Fairvalue10 May. 14 at 10:31 AM
$OCUL It’s still crazy this stagnation below USD 10. Axpaxli is completely de-risked, and today SOL-1 seems sufficient to move forward. The SPA with the FDA is critical here and provides a solid foundation, it’s a binding agreement on trial design and endpoints, which substantially reduces regulatory risk at the review stage. Dugel’s remarks indicate the NDA is imminent. We should be around 15 while awaiting the NDA filing and likely a buyout.
2 · Reply
davetoma
davetoma May. 14 at 5:59 AM
$OCUL the second ocul is down a penny tmoney comes out like a cockraoch from a dive bar lol yelling the sky is
0 · Reply
davetoma
davetoma May. 14 at 5:57 AM
$OCUL no posts from tmoney because he only posts when ocul is down lmao...it's like rooting for your favorite sports team and someone in the room is only loud when they are losing....this is grad school shit
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie May. 13 at 8:10 PM
$OCUL The BofA Conference was much better than the earnings call. Im really looking forward to june 17. Will be my last day in London. See if I’m sipping bubbly or shots of bourbon on my way home.
2 · Reply
WarrenDouglasTrader
WarrenDouglasTrader May. 13 at 2:00 PM
$OCUL how is this not bought out?
1 · Reply